We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer

By LabMedica International staff writers
Posted on 12 Mar 2025

Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. More...

However, this survival rate dramatically decreases to just 30% when the cancer is discovered at more advanced stages. One of the challenges in treating breast cancer, particularly aggressive forms such as triple-negative breast cancer, is the difficulty in quickly assessing treatment effectiveness. Often, doctors rely on chemotherapy regimens, which are expensive and toxic, continuing with treatment even when it proves ineffective. Typically, doctors cannot determine if a chemotherapy regimen is working until the patient has completed all the prescribed cycles, which can take up to six months. If the treatment is unsuccessful, the patient may need to begin a new regimen, starting the process over. Now, a simple blood test that searches for a biomarker in plasma will allow doctors to assess quickly whether cancer treatments, like chemotherapy, are working. This allows for faster adjustments to the treatment plan, switching to more effective therapies if necessary.

Previously, researchers have focused on nitric oxide production, a molecule that regulates cancer cell growth. Researchers at the University of New England (UNE, Portland, ME, USA) discovered a biomarker called Nw-hydroxy-L-Arginine (NOHA) that is a sensitive and reliable indicator for estrogen receptor-negative tumors, which are more aggressive types of breast cancer. Prior research had already linked nitric oxide, inflammatory biology, and breast cancer. The researchers realized that NOHA, being upstream of the nitric oxide process, could be measured through a blood test rather than a tissue sample. NOHA directly correlates with nitric oxide levels, without interference from other biological pathways. With this discovery, they began exploring NOHA as a biomarker for both detecting and monitoring breast cancer and even applied for a patent for a diagnostic tool that uses this blood marker to track aggressive, estrogen-negative tumors.

The researchers conducted a study in Tanzania to test whether NOHA could determine the estrogen receptor status in breast cancer patients. The results from this study were promising, suggesting that NOHA has the potential for improving cancer care. With the NOHA blood test, doctors could monitor NOHA levels after each treatment cycle. If the levels show an unfavorable change, the physician could pause the current drug combination and try another. Building on these findings, the team is now researching NOHA's role in managing triple-negative breast cancer in the U.S. through clinical trials, which are essential in translating laboratory results into real-world applications.

In addition, the team is exploring NOHA’s potential for early detection of breast cancer, particularly for individuals with genetic predispositions, and its role in drug development. Their work is setting the stage for more dynamic monitoring of treatment effectiveness. Following their success with breast cancer, the researchers have expanded their work to ovarian cancer. The American Cancer Society estimates that nearly 20,000 new cases of ovarian cancer will be diagnosed in the U.S. this year, with almost 13,000 women dying from the disease. Because the symptoms of ovarian cancer are often subtle or absent in its early stages, the disease is frequently diagnosed at a later, more advanced stage. The researchers' findings indicate that NOHA could also be used to detect and monitor ovarian cancer. This led them to secure a second patent for a blood diagnostic tool to identify ovarian cancer, broadening the impact of their groundbreaking research.

“It validates to us that (NOHA) is not only going to be centric to breast cancer, but it can also expand to other tumors like ovarian cancer,” said Srinidi (Sri) Mohan, Ph.D., professor at the University of New England School of Pharmacy, who identified NOHA as a potential biomarker for breast cancer detection and monitoring.

Related Links:
University of New England


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.